Alumis Inc. $ALMS Shares Sold by Trium Capital LLP

Trium Capital LLP lessened its stake in Alumis Inc. (NASDAQ:ALMS) by 71.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 893,107 shares of the company’s stock after selling 2,229,004 shares during the quarter. Alumis comprises approximately 6.8% of Trium Capital LLP’s investment portfolio, making the stock its 4th biggest holding. Trium Capital LLP owned approximately 0.86% of Alumis worth $8,717,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALMS. Stoneridge Investment Partners LLC increased its stake in shares of Alumis by 8.1% in the 3rd quarter. Stoneridge Investment Partners LLC now owns 29,535 shares of the company’s stock valued at $118,000 after buying an additional 2,210 shares during the period. Rhumbline Advisers increased its stake in shares of Alumis by 21.7% in the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after buying an additional 2,949 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Alumis by 320.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock valued at $26,000 after buying an additional 4,894 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Alumis by 64.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock valued at $77,000 after buying an additional 4,926 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in shares of Alumis by 104.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,770 shares of the company’s stock valued at $47,000 after buying an additional 6,027 shares during the period.

Analysts Set New Price Targets

ALMS has been the subject of several research reports. Loop Capital set a $37.00 target price on Alumis in a research note on Wednesday, January 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alumis in a research report on Monday, December 29th. Wells Fargo & Company lifted their price target on shares of Alumis from $17.00 to $39.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 6th. Leerink Partners lifted their price target on shares of Alumis from $20.00 to $32.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 6th. Finally, UBS Group reiterated an “outperform” rating on shares of Alumis in a research report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Alumis currently has an average rating of “Moderate Buy” and a consensus price target of $38.60.

Alumis Stock Up 1.0%

Shares of Alumis stock opened at $22.94 on Friday. Alumis Inc. has a 12 month low of $2.76 and a 12 month high of $30.60. The business has a fifty day simple moving average of $25.92 and a 200 day simple moving average of $15.55. The stock has a market cap of $2.92 billion, a PE ratio of -7.50 and a beta of -0.64.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). Alumis had a negative return on equity of 116.97% and a negative net margin of 1,011.75%.The company had revenue of $1.93 million for the quarter, compared to analyst estimates of $2.75 million. Analysts expect that Alumis Inc. will post -8.51 EPS for the current fiscal year.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.